Cannabis has been the focus of considerable debate, advocacy, and policy, generating both interest and misinformation. This presentation will highlight the differences between scientific, legal, and marketing terminology, overview the current regulation of cannabis-based products in the US, and highlight the importance of FDA oversight while conducting comprehensive clinical research.

In addition, this presentation will take a unique look into the practice of cannabis-based companies strategically sponsoring and publicizing the results of academic studies that lack robustness, transparency, and validity in order to give their products the façade of scientific legitimacy without undertaking the necessary and expensive, large-scale clinical trials required for FDA approval of drug treatments. This marketing tactic serves to mislead consumers, patients, health care professionals, and other stakeholders who may not understand the relative value of different forms of scientific evidence.

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.